SEC Form 3 · accession 0001178913-18-000137
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dov Tamarkin
Director
Period of report
Jan 1, 2018
Accepted (ET)
Jan 11, 2018 · 8:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | holding | — | — | — | 2,563,489 | I | See footnote | |
| Ordinary Shares | holding | — | — | — | 11,239 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF1 | $5.04 | holding | — | — | — | May 13, 2014 | May 13, 2018 | Ordinary Shares | 2,094 | — | I |
| OptionsF2 | $5.88 | holding | — | — | — | — | Dec 29, 2024 | Ordinary Shares | 24,000 | — | D |
| OptionsF3 | $6.77 | holding | — | — | — | — | Dec 29, 2024 | Ordinary Shares | 45,000 | — | D |
| OptionsF4 | $6.34 | holding | — | — | — | — | Mar 1, 2026 | Ordinary Shares | 100,000 | — | D |
| Restricted Share UnitsF5 | $0.00 | holding | — | — | — | — | — | Ordinary Shares | 5,625 | — | D |
Explanation of responses
- F1Shares and Warrants held by Tamarkin Medical Innovation Ltd., an Israeli company controlled by Dr. Dov Tamarkin
- F2The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date) and ending December 29, 2017
- F3Options vest over a period of four years from December 29, 2014 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending December 29, 2018
- F4Options vest over a period of four years from March 1, 2016 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending March 1, 2020
- F5The Restricted Share Units vest in equal installments every three months over the vesting period beginning October 15, 2017 and ending January 15, 2019.
Remarks
The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit List: Exhibit 24 - Power of Attorney